Guo Lanwei, Cai Lin, Zhu Chenxin, Zhang Xinglong, Fang Yi, Yang Haiyan
Abstract
ObjectiveTo analyze the incidence, mortality, and survival status and trends of lung cancer in China.
MethodsThe data of incidence, mortality, disability-adjusted life year (DALY), and survival status and trends of lung cancer in China were collected from GLOBOCAN 2020, Global Burden of Disease Study in 2019 (GBD2019) databases, and the CONCORD-3 project report. Joinpoint 5.0 software was used to analyze the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of lung cancer in China from 1990 to 2019. Data management was conducted by using Excel 2016, and relevant graphical representations were generated using the ggplot2 package in software R 4.2.1.
ResultsIn 2020, a total of 815 563 lung cancer cases were newly reported in China with the ASIR of 34.8/100 000, in which 539 181 cases were reported in men, with the ASIR of 47.8/100 000, and 276 382 cases were reported in women, with the ASIR of 22.8/100 000. A total of 714 699 lung cancer deaths were reported in 2020, with the ASMR of 30.2/100 000. Among these deaths, there were 471 546 deaths in men with the ASMR of 41.8/100 000, and 243 153 deaths in women with the ASMR of 19.7/100 000. From 1990 to 2019, the ASIR and ASMR of lung cancer in both men and women showed increasing trends (P<0.05). However, from 2010 to 2019, the ASIR and ASMR of lung cancer in men showed decreasing trends, with annual percent of change (APC) of -0.17% (95%CI: -0.24% - -0.09%) and -0.69% (95%CI: -0.79% - -0.59%), respectively. The ASIR and ASMR of lung cancer in women showed increasing trends from 2016 to 2019, with APC of 3.33% (95%CI: 2.73% - 3.88%) and 2.61% (95%CI: 1.99% - 3.28%), respectively. The five-year net survival rate for lung cancer was 19.8% in China (95%CI:19.4% - 20.2%) from 2010 to 2014.
ConclusionsThe morbidity and mortality of lung cancer in China remain at high levels, the prognosis of lung cancer was poor, and the disease burden of lung cancer would become more serious in the context of population aging, so three-level prevention of lung cancer should be implemented to address this problem. In addition, attention should be paid to the increasing trends of ASIR and ASMR of lung cancer in women in recent years. Further investigation of risk factors and targeted prevention are needed to curb the rising trend in the incidence of lung cancer in women.
Key words:
Neoplasm, lung; Epidemiology; China
Contributor Information
Guo Lanwei
Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Henan Office for Cancer Control and Research, the Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou 450008, China
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
Cai Lin
Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Henan Office for Cancer Control and Research, the Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou 450008, China
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
Zhu Chenxin
Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Henan Office for Cancer Control and Research, the Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou 450008, China
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
Zhang Xinglong
Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Henan Office for Cancer Control and Research, the Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou 450008, China
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
Fang Yi
Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Henan Office for Cancer Control and Research, the Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou 450008, China
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
Yang Haiyan
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
